PDL BioPharma Revenue 2006-2020 | PDLI

PDL BioPharma revenue from 2006 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
PDL BioPharma Annual Revenue
(Millions of US $)
2020 $
2019 $55
2018 $198
2017 $320
2016 $244
2015 $590
2014 $581
2013 $456
2012 $381
2011 $362
2010 $345
2009 $318
2008 $294
2007 $225
2006 $187
2005 $158
PDL BioPharma Quarterly Revenue
(Millions of US $)
2020-12-31
2020-06-30 $5
2020-03-31 $6
2019-12-31 $-4
2019-09-30 $44
2019-06-30 $7
2019-03-31 $7
2018-12-31 $45
2018-09-30 $68
2018-06-30 $47
2018-03-31 $39
2017-12-31 $68
2017-09-30 $63
2017-06-30 $144
2017-03-31 $45
2016-12-31 $66
2016-09-30 $54
2016-06-30 $21
2016-03-31 $103
2015-12-31 $178
2015-09-30 $125
2015-06-30 $138
2015-03-31 $150
2014-12-31 $117
2014-09-30 $165
2014-06-30 $163
2014-03-31 $137
2013-12-31 $116
2013-09-30 $100
2013-06-30 $149
2013-03-31 $92
2012-12-31 $92
2012-09-30 $85
2012-06-30 $126
2012-03-31 $77
2011-12-31 $73
2011-09-30 $84
2011-06-30 $122
2011-03-31 $83
2010-12-31 $76
2010-09-30 $86
2010-06-30 $120
2010-03-31 $62
2009-12-31 $58
2009-09-30 $71
2009-06-30 $126
2009-03-31 $63
2008-12-31 $69
2008-09-30 $69
2008-06-30 $107
2008-03-31 $50
2007-12-31 $50
2007-09-30 $61
2007-06-30 $89
2007-03-31 $59
2006-12-31 $60
2006-09-30 $111
2006-06-30 $104
2006-03-31 $91
2005-12-31 $84
2005-09-30 $77
2005-06-30 $81
2005-03-31 $39
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00